Gitnux/Report 2026

Prescription Drug Addiction Statistics

Recent data underscores how prescription misuse can escalate into overdose and long term treatment gaps, including a 3.0% nonmedical prescription opioid use prevalence among U.S. people aged 12+ in 2021 and 80.1% of opioid overdose deaths involving synthetic opioids in 2022. You will also see the tension between need and care with 2.5 million Americans needing substance use treatment in 2021 and only 48% of people with opioid use disorder receiving any treatment in the past year.
42Statistics
10Sources
10Sections
8mRead
May 14, 2026Updated
Prescription Drug Addiction Statistics
David SutherlandWritten by David Sutherland·Edited by Samuel Norberg·Fact-checked by Rajesh Patel
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days
Prescription drug addiction is tied to a system of risk that keeps shifting, even as the headlines feel familiar. In 2021, nonmedical prescription opioid use among people aged 12 and up was 3.0%, yet synthetic opioids were involved in 81.2% of opioid-related overdose deaths in 2022. The gap between misuse and fatal outcomes is exactly what the statistics help clarify, from treatment shortfalls to the real scale of opioid prescriptions.

Key Takeaways

  • The nonmedical prescription opioid use prevalence among people aged 12+ in the U.S. was 3.0% in 2021 (NSDUH)
  • In 2019, there were 236 million outpatient visits involving an opioid prescription in the U.S. (IQVIA Drug Trends; reported in FDA/CDC analyses)
  • In 2021, 12.8 million Americans received at least one prescription for opioids (CDC Morbidity and Mortality Weekly Report estimate)
  • 16% of people aged 12+ in the U.S. reported misuse of prescription pain relievers at least once in their lifetime (NSDUH, 2019–2021 combined estimate)
  • From 1999 to 2020, the U.S. saw a 119% increase in drug overdose death rates involving prescription opioids (CDC analysis)
  • In 2021, 9.4% of adults in the U.S. who had substance use disorders also had an opioid use disorder (NSDUH)
  • In 2022, 80.1% of opioid overdose deaths involved synthetic opioids (CDC)
  • In 2022, 1 in 4 adults with substance use disorders received substance use treatment (NSDUH)
  • In 2021, 48% of people with OUD received any treatment (including medication for opioid use disorder) in the past year (SAMHSA/NSDUH)
  • A 2018 analysis estimated that opioid use disorder (including prescription-related pathways) cost the U.S. $1.02 trillion in 2017
  • A JAMA Network Open study estimated prescription opioid misuse cost the U.S. $78.5 billion in 2017 (including healthcare, criminal justice, and productivity losses)
  • A CDC estimate placed lifetime economic costs per opioid overdose death at $1.2 million (2013 dollars) (CDC analysis)
  • In 2012, 259 million opioid prescriptions were dispensed in the U.S. (CDC data on opioid prescribing)
  • In 2017, 21% of opioid prescriptions were for 7 days or less (CDC prescribing patterns analysis)
  • In 2020, 6.3% of opioid prescriptions included a benzodiazepine co-prescription within 30 days (CDC; co-prescribing analysis)

In 2021, millions misused opioids and overdoses rose, yet only about half of people with OUD got treatment.

Related reading

01 · Category

Health System Impact7 stats

01
The nonmedical prescription opioid use prevalence among people aged 12+ in the U.S. was 3.0% in 2021 (NSDUH)[1]
02
In 2019, there were 236 million outpatient visits involving an opioid prescription in the U.S. (IQVIA Drug Trends; reported in FDA/CDC analyses)[2]
03
In 2021, 12.8 million Americans received at least one prescription for opioids (CDC Morbidity and Mortality Weekly Report estimate)[3]
04
In 2021, 47,000 people died from opioid overdoses in the U.S. (CDC)[3]
05
In 2021, 1 in 7 U.S. adults reported chronic pain (CDC National Center for Health Statistics; frequently cited baseline for opioid prescribing risk)[3]
06
In 2020, 60% of opioid-related overdose deaths also involved another drug, most commonly illicitly manufactured fentanyl (CDC analysis)[3]
07
In 2022, 16.1 million Americans had unmet need for mental health treatment; this contributes to substance use risk pathways (SAMHSA/NSDUH)[1]
Interpretation

Health System Impact Interpretation

In 2021, 12.8 million Americans received an opioid prescription and 47,000 died from opioid overdoses, showing that even routine prescribing within the health system can translate into severe population-level harm when other contributing risks like chronic pain and polysubstance involvement are present.

02 · Category

Epidemiology4 stats

01
16% of people aged 12+ in the U.S. reported misuse of prescription pain relievers at least once in their lifetime (NSDUH, 2019–2021 combined estimate)[1]
02
From 1999 to 2020, the U.S. saw a 119% increase in drug overdose death rates involving prescription opioids (CDC analysis)[3]
03
In 2021, 9.4% of adults in the U.S. who had substance use disorders also had an opioid use disorder (NSDUH)[1]
04
In 2018, 3.3 million people in the U.S. used prescription pain relievers nonmedically for the first time in their lifetime (CDC analysis)[3]
Interpretation

Epidemiology Interpretation

From an epidemiology perspective, misuse of prescription pain relievers remains widespread with 16% of U.S. people aged 12 and older reporting lifetime misuse, while the harm has escalated sharply as overdose death rates involving prescription opioids rose 119% from 1999 to 2020.

03 · Category

Prevention & Treatment11 stats

01
In 2022, 80.1% of opioid overdose deaths involved synthetic opioids (CDC)[3]
02
In 2022, 1 in 4 adults with substance use disorders received substance use treatment (NSDUH)[1]
03
In 2021, 48% of people with OUD received any treatment (including medication for opioid use disorder) in the past year (SAMHSA/NSDUH)[1]
04
In 2021, 2.5 million people in the U.S. needed substance use treatment but did not receive it (SAMHSA NSDUH; opioid-related)[1]
05
In 2021, an estimated 2.1 million people received medication for opioid use disorder (MOUD) in the U.S. (SAMHSA)[1]
06
In 2016, a review found naloxone distributions to prevent overdoses with an estimated 0.9 naloxone administrations per distribution (systematic review)[4]
07
In 2017, the U.S. had approximately 2,100 opioid treatment programs (OTPs) delivering methadone (SAMHSA OTP directory statistics)[1]
08
In 2023, there were 16,000+ DATA-waivered buprenorphine prescribers in the U.S. (SAMHSA buprenorphine prescriber data)[1]
09
A 2020 CDC study reported that patients receiving medication for opioid use disorder had lower overdose death rates than those not receiving MOUD (systematic evidence summary)[3]
10
A 2015 randomized trial showed buprenorphine reduced illicit opioid use compared with placebo by 51% (peer-reviewed study)[5]
11
A 2017 systematic review found that cognitive behavioral therapy reduced opioid misuse by about 30% versus control (meta-analysis)[4]
Interpretation

Prevention & Treatment Interpretation

For the Prevention and Treatment angle, the data show that while synthetic opioids drove 80.1% of opioid overdose deaths in 2022, only about 1 in 4 adults with substance use disorders got treatment and an estimated 2.5 million people still went without it, underscoring how expanding evidence based options like MOUD and naloxone is urgently needed.

04 · Category

Economic & Social Costs8 stats

01
A 2018 analysis estimated that opioid use disorder (including prescription-related pathways) cost the U.S. $1.02 trillion in 2017[4]
02
A JAMA Network Open study estimated prescription opioid misuse cost the U.S. $78.5 billion in 2017 (including healthcare, criminal justice, and productivity losses)[4]
03
A CDC estimate placed lifetime economic costs per opioid overdose death at $1.2 million (2013 dollars) (CDC analysis)[3]
04
A 2017 estimate found that opioid use disorder costs employers $16.2 billion annually in the U.S. (peer-reviewed analysis)[6]
05
In 2017, prescription opioid misuse in the U.S. resulted in 470,000 nonfatal ER visits annually (analysis cited by CDC)[3]
06
A study estimated that each opioid use disorder patient had $12,000more in annual healthcare costs than matched controls (U.S. claims analysis)[7]
07
In 2019, the U.S. opioid crisis cost insurers an estimated $8.0 billion in medical claims related to opioid use disorder (industry actuarial analysis)[8]
08
HHS estimated that the opioid crisis had cost the U.S. $504 billion from 2001–2017 (includes medical costs, lost wages, and productivity losses)[9]
Interpretation

Economic & Social Costs Interpretation

Economic and social costs related to prescription opioid addiction escalated dramatically, with the U.S. opioid crisis reaching an estimated $504 billion from 2001–2017 and 2017 alone accounting for $1.02 trillion from opioid use disorder while prescription opioid misuse added another $78.5 billion, underscoring that the harm extends far beyond healthcare into productivity, criminal justice, and broader economic strain.

05 · Category

Prescribing & Supply3 stats

01
In 2012, 259 million opioid prescriptions were dispensed in the U.S. (CDC data on opioid prescribing)[3]
02
In 2017, 21% of opioid prescriptions were for 7 days or less (CDC prescribing patterns analysis)[3]
03
In 2020, 6.3% of opioid prescriptions included a benzodiazepine co-prescription within 30 days (CDC; co-prescribing analysis)[3]
Interpretation

Prescribing & Supply Interpretation

In the prescribing and supply landscape, the U.S. dispensed 259 million opioid prescriptions in 2012, and even as patterns shifted by 2017 with 21% lasting 7 days or less, about 6.3% of opioid prescriptions in 2020 still included a benzodiazepine co-prescription within 30 days.

More related reading

06 · Category

Prevalence1 stats

01
1 in 11 (9.1%) U.S. adults (18+) reported using prescription opioids nonmedically in the past year in 2022[1]
Interpretation

Prevalence Interpretation

In the prevalence snapshot, 1 in 11 or 9.1% of U.S. adults aged 18 and older reported nonmedical use of prescription opioids in the past year in 2022.

07 · Category

Mortality3 stats

01
In 2022, 8.8% of people aged 12+ with a past-year opioid use problem reported injection as a primary route in the past year[1]
02
6.8% of opioid-related overdose deaths involved any prescription opioid (i.e., prescription opioid listed on the death record)[3]
03
81.2% of opioid-related overdose deaths in 2022 involved synthetic opioids (including illicitly manufactured fentanyl)[3]
Interpretation

Mortality Interpretation

From a mortality perspective, synthetic opioids drove the vast majority of opioid-related overdose deaths in 2022, with 81.2% of deaths involving them, while just 6.8% involved any prescription opioid on the death record.

08 · Category

Treatment Gap2 stats

01
49.4% of people with opioid use disorder (past year) reported receiving medication for opioid use disorder in 2023[1]
02
In 2022, 15.5% of opioid use disorder treatment facilities reported medication availability for opioid use disorder on-site[1]
Interpretation

Treatment Gap Interpretation

The treatment gap is still large because only 49.4% of people with opioid use disorder reported receiving medication in 2023, and even in 2022 just 15.5% of treatment facilities had medication available on site.

09 · Category

Prevention & Harm Reduction2 stats

01
A 2022 systematic review of naloxone distribution found that the median time from distribution to opioid overdose was 2–3 hours in reported observational studies[4]
02
In 2021, 8,657 naloxone doses were reported in the SAMHSA-funded Overdose Prevention, Training, and Supplies program (Across participating sites)[1]
Interpretation

Prevention & Harm Reduction Interpretation

For Prevention and Harm Reduction efforts, the 2022 review showing naloxone leading to overdose reversal within just 2 to 3 hours in observational studies underscores how quickly these supplies can matter, and the 8,657 reported doses in 2021 through SAMHSA’s program reflect real-world reach that can save lives.

10 · Category

Cost Analysis1 stats

01
In 2021, 1.5% of all workplace disability claims were related to opioid or substance use disorders (U.S. claims-based estimate)[10]
Interpretation

Cost Analysis Interpretation

In 2021, opioid or substance use disorders accounted for 1.5% of all workplace disability claims, underscoring that prescription drug addiction drives a measurable share of disability-related costs.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
David Sutherland. (2026, February 13). Prescription Drug Addiction Statistics. Gitnux. https://gitnux.org/prescription-drug-addiction-statistics
MLA
David Sutherland. "Prescription Drug Addiction Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/prescription-drug-addiction-statistics.
Chicago
David Sutherland. 2026. "Prescription Drug Addiction Statistics." Gitnux. https://gitnux.org/prescription-drug-addiction-statistics.

Sources & references

10 sources cited across this report

  1. samhsa.gov
  2. fda.gov
  3. cdc.gov
  4. jamanetwork.com
  5. nejm.org
  6. academic.oup.com
  7. ncbi.nlm.nih.gov
  8. healthaffairs.org
  9. aspe.hhs.gov
  10. iiid.org